VSTM Verastem, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1526119 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY25.8%
TTM EPS YoY57.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-193.7%
Net margin-178.4%
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-88.0%
ROIC (approx.)—
Asset turnover0.49x
Leverage & solvency
Liabilities / assets95.6%
Debt / equity0.00x
Current ratio1.93x
Interest coverage-141.93x
Cash quality & payout
Operating cash flow / net income0.89x
Accruals ratio-9.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $30.91M | $10.00M |
| R&D expense | $114.60M | $81.33M |
| SG&A expense | $81.15M | $43.62M |
| Operating income | -$170.13M | -$114.96M |
| Interest expense | $1.14M | $4.56M |
| Pretax income | -$209.47M | -$130.45M |
| Income tax | — | $185,000 |
| Net income | -$209.47M | -$130.64M |
| EBITDA | -$170.10M | -$114.93M |
| EPS (basic) | -3.02 | -3.66 |
| EPS (diluted) | -3.02 | -3.66 |
| Weighted avg. shares (diluted) | 69.31M | 35.71M |
| Balance sheet | ||
| Cash & equivalents | $204.99M | $89.06M |
| Inventory | $1.83M | — |
| Current assets | $223.41M | $94.96M |
| PP&E, net | — | $32,000 |
| Intangibles | $16.43M | — |
| Total assets | $246.44M | $101.54M |
| Current liabilities | $72.27M | $30.97M |
| Long-term debt | — | $40.72M |
| Total debt | — | $40.72M |
| Total liabilities | $189.25M | $130.43M |
| Shareholders' equity | $57.20M | -$28.89M |
| Net debt | — | -$48.34M |
| Shares outstanding | 77.74M | 44.78M |
| Cash flow statement | ||
| Operating cash flow | -$137.51M | -$104.77M |
| Capital expenditure | — | $28,000 |
| Free cash flow | — | -$104.80M |
| Investing cash flow | -$9.62M | $59.97M |
| Financing cash flow | $263.31M | $54.78M |
| Depreciation & amortization | $30,000 | $26,000 |
| Stock-based compensation | $9.40M | $7.34M |
Free plan shows the latest 2 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.